Cardiomyopathy laboratory findings: Difference between revisions
No edit summary |
Lina Yaqoub (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cardiomyopathy}} | {{Cardiomyopathy}} | ||
{{AE}} [[User:Lina Ya'qoub|Lina Ya'qoub, MD]] | |||
==Overview== | ==Overview== | ||
[[Hyponatremia]] can be seen in patients with cardiomypathy and other causes of [[HF]]: it has prognostic implications; as it indicates the activation of the [[renin-angiotensin system]] in response to the stress of the cardiomyopathy and/or [[heart failure]]. Kidney function could be affected as a result of medication-toxicity, volume depletion in cases of excessive [[diuresis]], or development of [[cardiorenal syndrome]]. [[Brain natriuretic peptide|Brain natriuretic peptide (BNP)]] is usually elevated in systolic heart dysfunction: it can also be falsely elevated in [[renal failure]] and [[pulmonary embolism]]. On the other hand, it can be falsely low in obese patients. | [[Hyponatremia]] can be seen in patients with cardiomypathy and other causes of [[HF]]: it has prognostic implications; as it indicates the activation of the [[renin-angiotensin system]] in response to the stress of the cardiomyopathy and/or [[heart failure]]. Kidney function could be affected as a result of medication-toxicity, volume depletion in cases of excessive [[diuresis]], or development of [[cardiorenal syndrome]]. [[Brain natriuretic peptide|Brain natriuretic peptide (BNP)]] is usually elevated in systolic heart dysfunction: it can also be falsely elevated in [[renal failure]] and [[pulmonary embolism]]. On the other hand, it can be falsely low in obese patients. | ||
Revision as of 20:28, 25 June 2019
|
Cardiomyopathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Guidelines |
|
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy |
|
Case Studies |
|
Cardiomyopathy laboratory findings On the Web |
|
American Roentgen Ray Society Images of Cardiomyopathy laboratory findings |
|
Risk calculators and risk factors for Cardiomyopathy laboratory findings |
Associate Editor(s)-in-Chief: Lina Ya'qoub, MD
Overview
Hyponatremia can be seen in patients with cardiomypathy and other causes of HF: it has prognostic implications; as it indicates the activation of the renin-angiotensin system in response to the stress of the cardiomyopathy and/or heart failure. Kidney function could be affected as a result of medication-toxicity, volume depletion in cases of excessive diuresis, or development of cardiorenal syndrome. Brain natriuretic peptide (BNP) is usually elevated in systolic heart dysfunction: it can also be falsely elevated in renal failure and pulmonary embolism. On the other hand, it can be falsely low in obese patients.
Cardiomyopathy Laboratory Findings
- Hyponatremia can be seen in patients with cardiomypathy and other causes of HF: it has prognostic implications; as it indicates the activation of the renin-angiotensin system in response to the stress of the cardiomyopathy and/or heart failure.[1]
- Kidney function could be affected as a result of medication-toxicity, volume depletion in cases of excessive diuresis, or development of cardiorenal syndrome.[1]
- Brain natriuretic peptide (BNP) is usually elevated in systolic heart dysfunction: it can also be falsely elevated in renal failure and pulmonary embolism. On the other hand, it can be falsely low in obese patients.
- Elevated troponin levels indicate ischemic heart disease, and should be investigated as much, till coronary arterial disease is ruled out.
- Elevated iron saturation and ferritin are indicative of hemochromatosis as a cause of cardiomyopathy.